Hims and Hers told investors it plans to begin selling sermorelin, glutathione, and NAD+ before the end of the year, moving a company with nearly three million subscribers into a wellness category built largely on claims that clinical trials have not tested.
Chief executive Andrew Dudum described the plan on the company's second-quarter earnings call, where it reported more than $753 million in revenue, up nearly 40 percent year over year, and raised full-year guidance to a range of $3.1 billion to $3.3 billion. According to Fierce Healthcare, patients seek these compounds for wellness and anti-aging purposes.
